Form D · Pharmaceuticals
SOLIGENIX, INC.
Princeton, NJ · CIK 0000812796
Offering snapshot reported Nov 8, 2017 · SEC filing
- Reported sold
- $1.96M Offering amount: $1.96M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 2, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2017 | Initial | $1,964,000 | No comparison | 6 | SEC filing |
| May 3, 2013 | Initial | $1,500,000 | No comparison | 1 | SEC filing |
| Jul 2, 2010 | Initial | $5,904,277 | No comparison | 46 | SEC filing |
| Mar 24, 2009 | Initial | $300,000 | No comparison | Not reported | SEC filing |
| Feb 27, 2009 | Initial | $4,500,000 | No comparison | Not reported | SEC filing |
| Feb 3, 2009 | Initial | $2,384,200 | No comparison | Not reported | SEC filing |
| Dec 5, 2008 | Initial | $1,500,000 | No comparison | Not reported | SEC filing |
| Feb 28, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 26, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Jan 19, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 25, 2006 | Paper | Not reported | No comparison | Not reported | |
| Feb 22, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $137K
- Form D file number
- 021-298360
Additionally, the Issuer agreed to (i) sell, for the price of $100, the placement agent a warrant to purchase 19,640 shares of common stock at a price of $2.50 per share and (iii) reimburse certain expenses of the placement agent.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Aegis Capital Corp. | 15007 |
Source: Form D, filed Nov 8, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert N Brey | Executive |
| Robert N. Brey, Ph.D. | Executive |
| Keith L. Brownlie, Cpa | Director |
| Keith L. Brownlie, C.P.A. | Director |
| Marco M. Brughera, Dvm | Director |
| Cyrille Buhrman | Director |
| R. Christopher Cavalli, Ph D | Executive |
| James Clavijo | Executive |
| Oreola Donini, Ph D | Executive |
| Brian Hamilton | Executive |
| Brian L. Hamilton, M.D., Ph.D. | Executive |
| Kevin J. Horgan, M.D. | Executive |
| Karen Krumeich | Executive |
| James S Kuo | Director |
| Greg A Lapointe | Director |
| Gregg A. Lapointe, C.P.A. | Director |
| Gregg A. La Pointe, Cpa | Director |
| Gregg A. Lapointe, C.P.A., M.B.A. | Director |
| Evan Myrainthopoulos | Director, Executive |
| Evan Myrianthopoulos | Director, Executive |
| Robert J. Rubin, Md | Director |
| Robert J. Rubin, M.D. | Director |
| Adam T. Rumage | Executive |
| Christopher J Schaber | Director, Executive |
| Christopher J. Schaber, Ph D | Director, Executive |
| Christopher J. Schaber, Ph.D. | Director, Executive |
| Christopher P. Schnittker, C.P.A. | Executive |
| Richard C. Straube, Md M Sc | Executive |
| Joseph M. Warusz, C.P.A. | Executive |
| Jerome B. Zeldis, M.D., Ph.D. | Director |
| Jerome B. Zeldis, Ph D | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
29 Emmons Drive Suite C 10
Princeton, NJ, 08540
Princeton, NJ, 08540